GD2 oligosaccharide: target for cytotoxic T lymphocytes - PubMed (original) (raw)
GD2 oligosaccharide: target for cytotoxic T lymphocytes
X J Zhao et al. J Exp Med. 1995.
Abstract
Carbohydrate antigens rarely provide target epitopes for cytotoxic T lymphocytes (CTL). Disialoganglioside GD2 is a glycolipid expressed at high levels in human tumors and a small group of murine lymphomas (EL4, RBL5, RMA, RMA-S, A13, and BALBRVE). Immunization of C57B1/6 mice with irradiated EL4 cells stimulated a specific CTL response and protected these animals from engraftment of EL4 lymphoma. The CTL activity resided in the CD4-CD8+ population, was dependent on T cell receptor alpha/beta, and was not removed by anti-natural killer cell immunoabsorption, but was restricted to GD2 and H-2b bearing targets. CTL activity could be completely inhibited by GD2-oligosaccharide-specific monoclonal antibodies and their F(ab')2 fragments, but not by immunoglobulin G3 myelomas or antibodies against GD3 or GM2. Soluble GD2 did not inhibit specific tumor lysis. RMA-S lymphoma cells (GD2+H-2b-TAP2 deficient) were resistant to GD2-specific CTL. Sialic acid-containing peptides eluted from EL4 lymphoma cells could (a) stabilize H-2 molecules on RMA-S cells and (b) sensitize them for GD2-specific CTL. Control peptides (derived from vesicular stomatitis virus nucleoprotein peptide and GD2-negative lymphomas) could also stabilize H-2 on RMA-S, but were resistant to GD2-specific CTL. These H-2-binding peptides could be purified by anti-GD2 affinity chromatography. We postulate a new class of naturally occurring epitopes for T cells where branched-chain oligosaccharides are linked to peptides with anchoring motifs for the major histocompatibility complex class I pocket. While analogous to the haptens trinitrophenyl and O-beta-linked acetyl-glucosamine, the potential implications of natural carbohydrates as antigenic epitopes for CTL in biology are considerable.
Similar articles
- Biology of GD2 ganglioside: implications for cancer immunotherapy.
Machy P, Mortier E, Birklé S. Machy P, et al. Front Pharmacol. 2023 Aug 21;14:1249929. doi: 10.3389/fphar.2023.1249929. eCollection 2023. Front Pharmacol. 2023. PMID: 37670947 Free PMC article. Review. - B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.
Johnston JV, Malacko AR, Mizuno MT, McGowan P, Hellström I, Hellström KE, Marquardt H, Chen L. Johnston JV, et al. J Exp Med. 1996 Mar 1;183(3):791-800. doi: 10.1084/jem.183.3.791. J Exp Med. 1996. PMID: 8642283 Free PMC article. - Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes.
Blake J, Johnston JV, Hellström KE, Marquardt H, Chen L. Blake J, et al. J Exp Med. 1996 Jul 1;184(1):121-30. doi: 10.1084/jem.184.1.121. J Exp Med. 1996. PMID: 8691125 Free PMC article. - Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL.
Kuhröber A, Schirmbeck R, Reimann J. Kuhröber A, et al. Eur J Immunol. 1994 May;24(5):1172-80. doi: 10.1002/eji.1830240525. Eur J Immunol. 1994. PMID: 7514132 - Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers.
Rossig C, Kailayangiri S, Jamitzky S, Altvater B. Rossig C, et al. Front Oncol. 2018 Nov 12;8:513. doi: 10.3389/fonc.2018.00513. eCollection 2018. Front Oncol. 2018. PMID: 30483473 Free PMC article. Review.
Cited by
- Biology of GD2 ganglioside: implications for cancer immunotherapy.
Machy P, Mortier E, Birklé S. Machy P, et al. Front Pharmacol. 2023 Aug 21;14:1249929. doi: 10.3389/fphar.2023.1249929. eCollection 2023. Front Pharmacol. 2023. PMID: 37670947 Free PMC article. Review. - Discovery of Cell-Surface Vimentin (CSV) as a Sarcoma Target and Development of CSV-Targeted IL12 Immune Therapy.
Batth IS, Li S. Batth IS, et al. Adv Exp Med Biol. 2020;1257:169-178. doi: 10.1007/978-3-030-43032-0_14. Adv Exp Med Biol. 2020. PMID: 32483739 Review. - Anti-GD2 immunotherapy for neuroblastoma.
Sait S, Modak S. Sait S, et al. Expert Rev Anticancer Ther. 2017 Oct;17(10):889-904. doi: 10.1080/14737140.2017.1364995. Epub 2017 Aug 14. Expert Rev Anticancer Ther. 2017. PMID: 28780888 Free PMC article. Review. - Tumor-Associated Glycans and Immune Surveillance.
Monzavi-Karbassi B, Pashov A, Kieber-Emmons T. Monzavi-Karbassi B, et al. Vaccines (Basel). 2013 Jun 17;1(2):174-203. doi: 10.3390/vaccines1020174. Vaccines (Basel). 2013. PMID: 26343966 Free PMC article. Review. - Cellular immunotherapy for pediatric solid tumors.
Hegde M, Moll AJ, Byrd TT, Louis CU, Ahmed N. Hegde M, et al. Cytotherapy. 2015 Jan;17(1):3-17. doi: 10.1016/j.jcyt.2014.05.019. Epub 2014 Jul 28. Cytotherapy. 2015. PMID: 25082406 Free PMC article. Review.
References
- Proc Natl Acad Sci U S A. 1982 Dec;79(24):7629-33 - PubMed
- Immunol Lett. 1993 Jan;35(1):63-8 - PubMed
- Int J Cancer. 1993 May 28;54(3):499-505 - PubMed
- J Immunol. 1993 Jul 15;151(2):678-87 - PubMed
- Int J Cancer. 1993 Sep 30;55(3):465-70 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials